Developer docs
API playgroundTry for free, no card

Search company profiles

EndoSpan

Full company profile

uuid0002jzo

Namestring
EndoSpan
Legal namestring
Endospan Ltd.
Websiteurl
endospan.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

EndoSpan Ltd. is an Israeli medical device company headquartered in Herzliya, founded in 2009 and operating with 51–100 employees until its acquisition by Artivion, Inc. in May 2026. The company develops endovascular implantable devices for the minimally invasive treatment of aortic arch disease, with its flagship product, the NEXUS® Aortic Arch Stent Graft System, positioned as the first off-the-shelf endovascular solution approved for chronic aortic arch dissections in patients at high risk for open surgical repair. The system is a modular branched platform combining an Arch Stent Graft with a brachiocephalic trunk branch, an Ascending Curved Stent Graft, and distal extension grafts that align via radiopaque markers and a through-and-through guidewire delivery technique to exclude the diseased arch while preserving antegrade flow to the supra-aortic vessels.

EndoSpan's business model centers on one-time hardware sales of a Class III capital implant to hospitals and surgical centers, supplemented by physician training, KOL proctoring, and clinical-evidence-driven adoption. From 2019 through May 2026, all EMEA commercial activity was executed via Artivion as exclusive distributor, and the company's clinical positioning is anchored by the TRIOMPHE IDE pivotal study in 94 high-surgical-risk patients demonstrating 0% one-year lesion-related mortality and a 1.1% one-year disabling stroke rate. Following FDA Premarket Approval in April 2026, a U.S. commercial launch is planned for January 2027, and the May 2026 acquisition by Artivion for $135 million upfront (plus up to $200 million contingent on U.S. commercial performance) integrates NEXUS alongside Artivion's AMDS and ARCEVO LSA into what Artivion describes as the only globally complete aortic arch portfolio.

Short descriptiontext

EndoSpan is an Israeli medical device company that develops the NEXUS Aortic Arch Stent Graft System, a first-in-class off-the-shelf endovascular implant for minimally invasive repair of chronic aortic arch dissections in high-surgical-risk patients, sold to vascular and cardiovascular surgery programs at tertiary hospitals.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHerzliya, Israel
HQ citystring
Herzliya
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
endovascular stent grafts, aortic arch repair, vascular medical devices, branched stent systems, minimally invasive surgery
Industry2 codes
PRIMARYHLAHAFAF
Endovascular Aortic Repair (EVAR/TEVAR) & Aortic Grafts
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAH
Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Endovascular Medical Devices (Aortic Stent Grafts)
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical device (capital implant) sales
TypeHardware Sales
Description

Endospan generates revenue primarily through one-time sales of its NEXUS® Aortic Arch Stent Graft System to hospitals and surgical centers. Pre-acquisition, EMEA sales were executed via Artivion as exclusive distributor; post-May 2026 acquisition, revenue flows into Artivion's consolidated medical-device sales line.

prnewswire.com
2Distribution / supply agreement revenue
TypeLicensing Royalties
Description

From 2019 through May 2026, Artivion served as Endospan's exclusive distributor of the NEXUS System across EMEA, generating revenue for Endospan through product supply to Artivion at agreed transfer terms.

prnewswire.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others, Supply Chain
Pricing details1 tier
1Enterprise quote-based pricing for hospital procurement of NEXUS implantable stent graft systems (not publicly disclosed).
ModelOtherBilling cadenceMulti-year contract
Notes

Not publicly disclosed; pricing varies by geography, hospital contract, and volume. Acquisition valuation: $135M upfront + up to $200M contingent on U.S. NEXUS commercial performance over two years (alternative reporting: $175M less loan offsets).

stocktitan.net
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1NEXUS Aortic Arch Stent Graft System
Description

Endovascular branched stent graft system for minimally invasive treatment of aortic arch disease, including chronic dissections, in high-risk patients unsuitable for open surgical repair; received FDA premarket approval in April 2026.

endospan.com
Core offering1 text field

EndoSpan develops and manufactures the NEXUS Aortic Arch Stent Graft System, a Class III branched endovascular implant for the minimally invasive treatment of chronic aortic arch dissections in patients at high risk for open surgical repair. The modular system combines an Arch Stent Graft (with a brachiocephalic trunk branch), an Ascending Curved Stent Graft, and distal extension Stent Grafts that connect via radiopaque marker alignment to seal the arch while preserving flow to the supra-aortic vessels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 0% one-year lesion-related mortality in 94 high-surgical-risk patients (down from 6.4% at 30 days)
+4 more records
Product and service1 record
1NEXUS Aortic Arch Stent Graft System
CategoryEndovascular Medical Devices
Description

Class III branched endovascular stent graft system indicated for endovascular treatment of chronic dissections involving the aortic arch in patients at high risk for open surgical repair. Combines an Arch Stent Graft (with a brachiocephalic trunk branch), an Ascending Curved Stent Graft, and distal extension (DE) Stent Grafts connected via radiopaque marker alignment to seal the arch while preserving flow to supra-aortic vessels. Sold to hospitals and tertiary surgical centers for implantation by vascular and cardiovascular surgeons.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Artivion has been Endospan's exclusive distributor of the NEXUS System across the EMEA region since 2019. Following FDA PMA approval of NEXUS in April 2026, Artivion exercised its option and completed the acquisition of Endospan on May 18, 2026 for a $135 million upfront net purchase price (funded via a previously drawn $150 million delayed draw term loan), with additional contingent consideration of up to $200 million tied to U.S. NEXUS commercial performance over two years. Post-acquisition, Endospan becomes part of Artivion's aortic arch portfolio alongside AMDS and ARCEVO LSA, creating what the company calls the only complete aortic arch portfolio globally.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Kevin Mayberry (Endospan's CEO) was a 14-year Endologix executive. Endologix focuses primarily on infrarenal AAA devices rather than arch, so it is an adjacent vascular medtech company rather than a direct arch competitor, but highly comparable in business model and clinical specialty.

2Cook Medical
TypeDirect peer
Description

Direct competitor with the Zenith thoracic and arch endograft lines, including branched and fenestrated arch systems. Competes with Endospan NEXUS in the endovascular aortic arch repair space serving vascular surgeons at tertiary centers.

TypeBroad incumbent
Description

Broad incumbent in vascular surgery with the Valiant thoracic stent graft system and Captivia delivery platform. Medtronic is a much larger player with broader endovascular and surgical portfolios, but its thoracic offering overlaps directly with NEXUS in the aortic arch disease indication.

TypeEmerging player
Description

A vascular-focused interventional medtech company expanding into adjacent aortic and embolization indications. While not a direct arch competitor today, it represents a relevant emerging player in the broader endovascular interventional space Endospan serves.

TypeBroad incumbent
Description

Now Endospan's parent company following the May 2026 acquisition, Artivion also markets the AMDS hybrid prosthesis and ARCEVO LSA — adjacent aortic arch solutions that, combined with NEXUS, form what the company calls the only complete aortic arch portfolio globally.

TypeDirect peer
Description

A leading direct competitor in the aortic arch and thoracic stent graft space via its Relay and custom-made arch branch programs (formerly Bolton Medical, Vascutek). Competes with Endospan NEXUS for the same high-risk arch disease patient population and vascular surgeon call points, particularly in Europe.

7MicroPort Scientific
TypeEmerging player
Description

Has developed the Castor branched thoracic stent graft system, a single-branch arch product that competes with NEXUS in the arch dissection indication. MicroPort is an emerging global player in the thoracic endovascular space.

TypeDirect peer
Description

Direct competitor via its Gore TAG and Gore Excluder thoracic stent graft systems, with arch branch programs in development. Gore is a long-established incumbent in endovascular aortic repair and competes directly with NEXUS for hospital procurement dollars.

TypeEmerging player
Description

Chinese-headquartered medical device company with aortic stent graft products including the Ankara and Hercules series, with expanding arch indications. Represents a lower-cost emerging alternative to NEXUS, particularly in Asia-Pacific markets.

TypeDirect peer
Description

Markets the E-vita and E-nside thoracic stent graft systems used for endovascular aortic arch repair. Competes with Endospan NEXUS in the European market and is pursuing expanded indications for branched arch disease.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EndoSpan

Endovascular Medical Devices (Aortic Stent Grafts)endospan.com

EndoSpan is an Israeli medical device company that develops the NEXUS Aortic Arch Stent Graft System, a first-in-class off-the-shelf endovascular implant for minimally invasive repair of chronic aortic arch dissections in high-surgical-risk patients, sold to vascular and cardiovascular surgery programs at tertiary hospitals.

What EndoSpan does

EndoSpan Ltd. is an Israeli medical device company headquartered in Herzliya, founded in 2009 and operating with 51–100 employees until its acquisition by Artivion, Inc. in May 2026. The company develops endovascular implantable devices for the minimally invasive treatment of aortic arch disease, with its flagship product, the NEXUS® Aortic Arch Stent Graft System, positioned as the first off-the-shelf endovascular solution approved for chronic aortic arch dissections in patients at high risk for open surgical repair. The system is a modular branched platform combining an Arch Stent Graft with a brachiocephalic trunk branch, an Ascending Curved Stent Graft, and distal extension grafts that align via radiopaque markers and a through-and-through guidewire delivery technique to exclude the diseased arch while preserving antegrade flow to the supra-aortic vessels.

EndoSpan's business model centers on one-time hardware sales of a Class III capital implant to hospitals and surgical centers, supplemented by physician training, KOL proctoring, and clinical-evidence-driven adoption. From 2019 through May 2026, all EMEA commercial activity was executed via Artivion as exclusive distributor, and the company's clinical positioning is anchored by the TRIOMPHE IDE pivotal study in 94 high-surgical-risk patients demonstrating 0% one-year lesion-related mortality and a 1.1% one-year disabling stroke rate. Following FDA Premarket Approval in April 2026, a U.S. commercial launch is planned for January 2027, and the May 2026 acquisition by Artivion for $135 million upfront (plus up to $200 million contingent on U.S. commercial performance) integrates NEXUS alongside Artivion's AMDS and ARCEVO LSA into what Artivion describes as the only globally complete aortic arch portfolio.

EndoSpan firmographics

Firmographics
Name
EndoSpan
Legal name
Endospan Ltd.
Website
https://endospan.com
Company type
Private
Founded year
2009
Operating status
Acquired
Headcount range
51–100 employees
Short description
EndoSpan is an Israeli medical device company that develops the NEXUS Aortic Arch Stent Graft System, a first-in-class off-the-shelf endovascular implant for minimally invasive repair of chronic aortic arch dissections in high-surgical-risk patients, sold to vascular and cardiovascular surgery programs at tertiary hospitals.
Ownership category
akta.pro rank

EndoSpan industry classification

Industry
Product category
Endovascular Medical Devices (Aortic Stent Grafts)
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAFAF
Endovascular Aortic Repair (EVAR/TEVAR) & Aortic Grafts
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAH
Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Endovascular stent grafts
  • Aortic arch repair
  • Vascular medical devices
  • Branched stent systems
  • Minimally invasive surgery

Where EndoSpan is headquartered

Location

Headquarters

HQ city
Herzliya
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

EndoSpan business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others, Supply Chain

Revenue model

  1. Medical device (capital implant) sales: Endospan generates revenue primarily through one-time sales of its NEXUS® Aortic Arch Stent Graft System to hospitals and surgical centers. Pre-acquisition, EMEA sales were executed via Artivion as exclusive distributor; post-May 2026 acquisition, revenue flows into Artivion's consolidated medical-device sales line.
  2. Distribution / supply agreement revenue: From 2019 through May 2026, Artivion served as Endospan's exclusive distributor of the NEXUS System across EMEA, generating revenue for Endospan through product supply to Artivion at agreed transfer terms.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise quote-based pricing for hospital procurement of NEXUS implantable stent graft systems (not publicly disclosed).

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

EndoSpan product offering

Product offering

Core offering

EndoSpan develops and manufactures the NEXUS Aortic Arch Stent Graft System, a Class III branched endovascular implant for the minimally invasive treatment of chronic aortic arch dissections in patients at high risk for open surgical repair. The modular system combines an Arch Stent Graft (with a brachiocephalic trunk branch), an Ascending Curved Stent Graft, and distal extension Stent Grafts that connect via radiopaque marker alignment to seal the arch while preserving flow to the supra-aortic vessels.

Differentiator

Problem solved

Functional benefit

Brands

  • NEXUS Aortic Arch Stent Graft System: Endovascular branched stent graft system for minimally invasive treatment of aortic arch disease, including chronic dissections, in high-risk patients unsuitable for open surgical repair; received FDA premarket approval in April 2026.

Products and services

  • NEXUS Aortic Arch Stent Graft System Class III branched endovascular stent graft system indicated for endovascular treatment of chronic dissections involving the aortic arch in patients at high risk for open surgical repair. Combines an Arch Stent Graft (with a brachiocephalic trunk branch), an Ascending Curved Stent Graft, and distal extension (DE) Stent Grafts connected via radiopaque marker alignment to seal the arch while preserving flow to supra-aortic vessels. Sold to hospitals and tertiary surgical centers for implantation by vascular and cardiovascular surgeons.

Quantifiable outcome

  • 0% one-year lesion-related mortality in 94 high-surgical-risk patients (down from 6.4% at 30 days)
  • +4 more outcomes

Companies that use EndoSpan

Customer profile

Segments3 records

Ideal customer profiles2 records

EndoSpan technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

EndoSpan partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Artivion, Inc.flagshipStrategic or Co-development Partner · 1 January 2019Artivion has been Endospan's exclusive distributor of the NEXUS System across the EMEA region since 2019. Following FDA PMA approval of NEXUS in April 2026, Artivion exercised its option and completed the acquisition of Endospan on May 18, 2026 for a $135 million upfront net purchase price (funded via a previously drawn $150 million delayed draw term loan), with additional contingent consideration of up to $200 million tied to U.S. NEXUS commercial performance over two years. Post-acquisition, Endospan becomes part of Artivion's aortic arch portfolio alongside AMDS and ARCEVO LSA, creating what the company calls the only complete aortic arch portfolio globally.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

EndoSpan competitors and assessment

Company assessment

Others

  • Endologix: Kevin Mayberry (Endospan's CEO) was a 14-year Endologix executive. Endologix focuses primarily on infrarenal AAA devices rather than arch, so it is an adjacent vascular medtech company rather than a direct arch competitor, but highly comparable in business model and clinical specialty.

Direct peers

  • Cook Medical: Direct competitor with the Zenith thoracic and arch endograft lines, including branched and fenestrated arch systems. Competes with Endospan NEXUS in the endovascular aortic arch repair space serving vascular surgeons at tertiary centers.
  • Terumo Aortic: A leading direct competitor in the aortic arch and thoracic stent graft space via its Relay and custom-made arch branch programs (formerly Bolton Medical, Vascutek). Competes with Endospan NEXUS for the same high-risk arch disease patient population and vascular surgeon call points, particularly in Europe.
  • W. L. Gore & Associates: Direct competitor via its Gore TAG and Gore Excluder thoracic stent graft systems, with arch branch programs in development. Gore is a long-established incumbent in endovascular aortic repair and competes directly with NEXUS for hospital procurement dollars.
  • JOTEC (CryoLife subsidiary): Markets the E-vita and E-nside thoracic stent graft systems used for endovascular aortic arch repair. Competes with Endospan NEXUS in the European market and is pursuing expanded indications for branched arch disease.

Broad incumbents

  • Medtronic: Broad incumbent in vascular surgery with the Valiant thoracic stent graft system and Captivia delivery platform. Medtronic is a much larger player with broader endovascular and surgical portfolios, but its thoracic offering overlaps directly with NEXUS in the aortic arch disease indication.
  • Artivion: Now Endospan's parent company following the May 2026 acquisition, Artivion also markets the AMDS hybrid prosthesis and ARCEVO LSA — adjacent aortic arch solutions that, combined with NEXUS, form what the company calls the only complete aortic arch portfolio globally.

Emerging players

  • Penumbra: A vascular-focused interventional medtech company expanding into adjacent aortic and embolization indications. While not a direct arch competitor today, it represents a relevant emerging player in the broader endovascular interventional space Endospan serves.
  • MicroPort Scientific: Has developed the Castor branched thoracic stent graft system, a single-branch arch product that competes with NEXUS in the arch dissection indication. MicroPort is an emerging global player in the thoracic endovascular space.
  • Lifetech Scientific: Chinese-headquartered medical device company with aortic stent graft products including the Ankara and Hercules series, with expanding arch indications. Represents a lower-cost emerging alternative to NEXUS, particularly in Asia-Pacific markets.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

EndoSpan social profiles

Digital presence

EndoSpan financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EndoSpan leadership team

Management profile

Number of profiles

Profiles9 records

EndoSpan funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EndoSpan M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EndoSpan

What does EndoSpan do?

EndoSpan develops and manufactures the NEXUS Aortic Arch Stent Graft System, a Class III branched endovascular implant for the minimally invasive treatment of chronic aortic arch dissections in patients at high risk for open surgical repair. The modular system combines an Arch Stent Graft (with a brachiocephalic trunk branch), an Ascending Curved Stent Graft, and distal extension Stent Grafts that connect via radiopaque marker alignment to seal the arch while preserving flow to the supra-aortic vessels.

Is EndoSpan a public or private company?

EndoSpan is a private company. It is classified as corporate owned and is currently acquired.

When was EndoSpan founded?

EndoSpan was founded in 2009. It employs 51 to 100 people.

Where is EndoSpan based?

EndoSpan is headquartered in Herzliya, Israel, in the Middle East region.

How does EndoSpan make money?

Two revenue lines are on record. Medical device (capital implant) sales are the primary driver. The others are distribution / supply agreement revenue.

Who are EndoSpan's main competitors?

Endologix is listed as an others. Direct peers are Cook Medical, Terumo Aortic, W. L. Gore & Associates and JOTEC (CryoLife subsidiary). Broad incumbents are Medtronic and Artivion. Emerging players are Penumbra, MicroPort Scientific and Lifetech Scientific.

Does EndoSpan have an API?

No public API is recorded for EndoSpan.

What industry is EndoSpan in?

EndoSpan's product category is Endovascular Medical Devices (Aortic Stent Grafts). Its primary akta.pro industry code is HLAHAFAF, Endovascular Aortic Repair (EVAR/TEVAR) & Aortic Grafts, with a secondary code of HLAHAFAH, Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooAORT Q2 Deep Dive: Product Momentum and Pipeline Expansion Support Positive OutlookArtivion reported Q2 CY2026 results with revenue of $125.8 million, up 11.3% year-on-year and beating analyst estimates by 4.4%, while non-GAAP EPS of $0.13 exceeded consensus by 34.5%. The company reconfirmed full-year revenue guidance of $488 million and EBITDA guidance of $95.5 million, though operating margin declined to -6.7% from 7.4% in the prior year quarter. Management cited strong adoption of On-X heart valves and stent grafts, the FDA approval of the AMDS hybrid prosthesis, and the recent acquisition of Endospan's NEXUS system as key drivers for anticipated sequential improvements in the second half of the year.Medical BuyerArtivion revenue up 11% to USD 125.8M in Q2 2026Artivion, Inc announced its financial results for the second quarter ending June 30, 2026, reporting revenue of $125.8 million, an 11% increase compared to the same period in 2025. Significant growth was driven by On-X and stent grafts, with On-X revenue rising 18%. The company also completed the acquisition of Endospan Ltd. and received FDA approval for its AMDS Hybrid Prosthesis, enhancing its position in the aortic arch market.PR NewswireArtivion Reports Second Quarter 2026 Financial ResultsArtivion, Inc. reported second quarter 2026 financial results with total revenues of $125.8 million, representing an 11% increase on a GAAP basis and 9% on a constant currency basis compared to Q2 2025, while posting a GAAP net loss of $13.5 million but non-GAAP net income of $6.3 million. The company achieved two significant milestones during the quarter: receiving U.S. FDA PMA approval for the AMDS Hybrid Prosthesis and completing the acquisition of Endospan Ltd., which brought the NEXUS Aortic Arch Stent Graft System into Artivion's portfolio. Artivion reiterated its full-year 2026 revenue guidance of $480 to $496 million and adjusted EBITDA guidance of $92 to $99 million.Mpo-magArtivion Wins FDA Nod for AMDS Hybrid ProsthesisArtivion received FDA PMA approval for its AMDS Hybrid Prosthesis for acute Debakey Type I aortic dissections with malperfusion. The PERSEVERE trial showed a 72% reduction in 30-day mortality and zero distal anastomotic new entry tears. The company expects the approval to accelerate adoption.Pulse 2.0Artivion: $135 Million Endospan Acquisition Expands Aortic Arch PortfolioArtivion has completed the acquisition of Endospan Ltd., its long-standing partner focused on endovascular repair of aortic arch disease, for an upfront net purchase price of $135 million. The transaction was funded using a previously drawn $150 million delayed draw term loan, with potential additional consideration tied to commercial performance, and follows the FDA's premarket approval of the NEXUS branched endovascular stent graft system in April 2026. The acquisition combines Endospan's NEXUS platform with Artivion's existing AMDS and ARCEVO LSA technologies, creating what the company claims is the only complete aortic arch portfolio globally.MassDeviceArtivion closes $175M acquisition of aortic arch maker EndospanArtivion has completed the $175 million acquisition of Endospan, a manufacturer of aortic arch medical devices, following FDA approval for its Nexus system. The transaction includes potential additional consideration of up to $200 million based on the device's commercial performance in the U.S. over the next two years. Artivion intends to leverage its global distribution network to launch Nexus in the United States, building on its existing presence in EMEA.Investing.comArtivion completes $135 million Endospan acquisition By Investing.comArtivion, Inc. announced the completion of its acquisition of Endospan Ltd., an Israeli medical device company specializing in endovascular repair of aortic arch disease and developer of the NEXUS Aortic Arch System, for $135 million upfront funded through a delayed draw term loan. The deal strengthens Artivion's aortic device portfolio, combining NEXUS with its existing AMDS and ARCEVO LSA products to create what the company claims is the only complete portfolio of aortic arch solutions globally, following FDA approval of the NEXUS branched endovascular stent graft system in April 2026. Artivion's stock has declined 50% year-to-date, and while the company reported Q1 2026 earnings that beat expectations, it has adjusted its full-year 2026 revenue and EBITDA guidance downward by approximately 200 basis points.Stock TitanArtivion completes Endospan buy after FDA NEXUS approvalArtivion, Inc. has completed its acquisition of Endospan for $175M (less offsets for previously provided loans) plus up to $200M in contingent payments tied to U.S. NEXUS commercial performance over two years, following the April 2026 FDA PMA approval of the NEXUS® Aortic Arch System. The NEXUS system is the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in high-risk patients unsuitable for open surgical repair. The acquisition positions Artivion as the only company globally with a complete portfolio of aortic arch solutions, combining the NEXUS platform with its existing AMDS and ARCEVO LSA products.Stock TitanArtivion closes $135M Endospan aortic arch dealArtivion, Inc. has completed its acquisition of Endospan Ltd. for a $135 million upfront net purchase price, funded through its previously drawn $150 million delayed draw term loan, with additional potential consideration contingent on commercial performance. The deal grants Artivion full ownership of the NEXUS Aortic Arch System, which received FDA premarket approval in April 2026, completing what the company calls a "three-pronged aortic arch portfolio." Endospan, headquartered in Israel, had been Artivion's exclusive distributor of the NEXUS System across EMEA since 2019.PR NewswireArtivion Completes Acquisition of Endospan Ltd.Artivion, Inc. completed its acquisition of Endospan Ltd. on May 18, 2026, funding the $135 million upfront net purchase price using a previously drawn $150 million delayed draw term loan, with additional contingent consideration based on commercial performance. The FDA approved the NEXUS branched endovascular stent graft system in April 2026, and Artivion has been the exclusive distributor of the NEXUS System across EMEA since 2019. The acquisition positions Artivion as the only company globally with a complete portfolio of aortic arch solutions, including a pipeline of next-generation arch technologies.